Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

NCT00227188

Last updated date
Study Location
Pfizer Investigational Site
Bilbao, , 48903, Spain
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Invasive Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-5
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.

- Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Invasive Pneumococcal DiseaseImmune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine NCT00853749
  1. Reykjavik,
ALL GENDERS
5 Years+
years
MULTIPLE SITES
Invasive Pneumococcal DiseaseStudy Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease NCT01128439
  1. Oakland, California
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
Official Title Effectiveness of Prevnar in the Prevention on IPD in the Paediatric Population in Spain
Brief Summary The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)
Detailed Description Not Provided
Study Type Observational
Study Design Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
Samples without DNA
Sampling Method Non-Probability Sample
Study Population All public and private hospitals with a pediatric department belonging to one of the two autonomous communities.
Condition Invasive Pneumococcal Disease
Intervention Drug: Pneumococcal 7-valent conjugate vaccine Prevnar
Other Name: PREVNAR
Study Groups/Cohorts 1
Children from 0-5 years of age evaluated for IPD
Intervention: Drug: Pneumococcal 7-valent conjugate vaccine Prevnar
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: November 28, 2012)
408
Original Enrollment
 (submitted: September 13, 2005)
500
Actual Study Completion Date December 2005
Actual Primary Completion Date December 2005   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.
  • Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.
Sex/Gender
Sexes Eligible for Study:All
Ages up to 5 Years   (Child)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Spain
Removed Location Countries  
 
Administrative Information
NCT Number NCT00227188
Other Study ID Numbers 0887-101317
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2012